Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Dec 1;17(12):e0277313.
doi: 10.1371/journal.pone.0277313. eCollection 2022.

Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study

Yusuke Orii  1 , Eriko Kunikane  2 , Yutaka Yamada  1 , Masakazu Morioka  1 , Kentaro Iwasaki  1 , Shogo Arimura  1 , Akemi Mizuno  2 , Masaru Inatani  1
Affiliations
Clinical Trial

Brimonidine and timolol concentrations in the human vitreous and aqueous humors after topical instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution: An interventional study

Yusuke Orii et al. PLoS One. .

Abstract

Purpose: To evaluate the concentrations of brimonidine and timolol in the vitreous and aqueous humors after instillation of a 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution.

Methods: This single-arm open-label interventional study included patients with macular holes or idiopathic epiretinal membranes who were scheduled for vitrectomy. Written informed consent was obtained from all participants. A 0.1% brimonidine tartrate and 0.5% timolol fixed-combination ophthalmic solution was administered topically twice daily for 1 week preoperatively. The vitreous and aqueous humors were sampled before vitrectomy, and brimonidine and timolol concentrations were quantified using liquid chromatography-tandem spectrometry. This study was registered with the Japan Registry of Clinical Trials (jRCT, ID jRCTs051200008; date of access and registration: April 28, 2020). The study protocol was approved by the University of Fukui Certified Review Board (CRB) and complied with the tenets of the Declaration of Helsinki.

Results: Eight eyes of eight patients (7 phakic eyes and 1 pseudophakic eye) were included in this study. The mean brimonidine concentrations in the vitreous and aqueous humors were 5.04 ± 4.08 nM and 324 ± 172 nM, respectively. Five of the eight patients had brimonidine concentrations >2 nM in the vitreous humor, which is necessary to activate α2 receptors. The mean timolol concentrations in the vitreous and aqueous humors were 65.6 ± 56.0 nM and 3,160 ± 1,570 nM, respectively. Brimonidine concentrations showed significant positive correlations with timolol concentrations in the vitreous humor (P < 0.0001, R2 = 0.97) and aqueous humor (P < 0.0001, R2 = 0.96).

Conclusions: The majority of patients who received a 0.1% brimonidine tartrate and 0.5% timolol topical fixed-combination ophthalmic solution showed a brimonidine concentration >2 nM in the vitreous humor. Brimonidine and timolol may be distributed in the ocular tissues through an identical pathway after topical instillation.

PubMed Disclaimer

Conflict of interest statement

The authors have read the journal’s policy and have the following competing interests: MI, EK, and AM are paid employees of Senju Pharmaceutical Co., Ltd. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.

Figures

Fig 1
Fig 1. CONSORT flow diagram.
Fig 2
Fig 2. Brimonidine concentrations in the vitreous and the aqueous humors.
The solid horizontal line in each column indicates the mean of the included data points, and the dotted line parallel to the x-axis denotes the 2 nM brimonidine concentration that was shown to be neuroprotective in animals. The filled and open circles indicate vitreous humor and aqueous humor concentrations, respectively.
Fig 3
Fig 3. Correlations between drug concentrations in the aqueous and vitreous humors.
There was no significant correlation of the brimonidine (a) and the timolol (b) concentrations between in the aqueous humor and the vitreous.
Fig 4
Fig 4. Timolol concentrations in the vitreous and the aqueous humors.
The solid horizontal line in each column indicates the mean of included data points. The filled and open circles indicate concentrations in the vitreous humor and aqueous humor, respectively.
Fig 5
Fig 5. Linear correlations between brimonidine and timolol concentrations in the vitreous and aqueous humors.
The filled and open circles indicate concentrations in the vitreous humor and aqueous humor, respectively.
See this image and copyright information in PMC

References

    1. Quigley H. A., Addicks E. M., Green W. R., “Optic Nerve Damage in Human Glaucoma II. The Site of Injury and Susceptibility to Damage.,” Arch Ophthalmol., 99(4):635–649, 1981. - PubMed
    1. Ismail R., Azuara-Blanco A., Ramsay C. R., “Variation of clinical outcomes used in glaucoma randomised controlled trials: a systematic review.,” Br J Ophthalmol., 98(4):464–8, 2014. doi: 10.1136/bjophthalmol-2013-304323 - DOI - PubMed
    1. De Moraes C. G., Liebmann J. M., Levin L.A., “Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.,” Prog Retin Eye Res., 56:107–147, 2017. doi: 10.1016/j.preteyeres.2016.10.001 - DOI - PMC - PubMed
    1. Heijl A.,Leske M. C., Bengtsson B., “Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial.,” Arch Ophthalmol., 120(10):1268–79, 2002. doi: 10.1001/archopht.120.10.1268 - DOI - PubMed
    1. Kass M.A., Heuer D. K., Higginbotham E. J., “The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.,” Arch Ophthalmol., 120(6):701–13; discussion 829–30, 2002. doi: 10.1001/archopht.120.6.701 - DOI - PubMed

Publication types